Skip to main content
Fig. 7 | Journal of Hematology & Oncology

Fig. 7

From: Nanobody-based trispecific T cell engager (Nb-TriTE) enhances therapeutic efficacy by overcoming tumor-mediated immunosuppression

Fig. 7

The preliminary safety profile of the Nb-TriTE. ALT/AST ratios (A) and ALT (B) and AST (C) levels in the experiment. The levels of IL-6 (D) and IL-1β (E) after treatment. F Representative HE staining of the major organs (heart, liver, spleen, lung, kidney) of mice after different treatments. Scale bar, 100 μm. No obvious histological difference was observed after Nb-TriTE treatment

Back to article page

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us